Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-fluoro-5-ethylarabinosyluracil
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Intraperitoneal
01
Overview
2'-fluoro-5-ethylarabinosyluracil (FAU, also known as FEAU) is a synthetic nucleoside analog belonging to the pyrimidine class. It has been investigated primarily for its antiviral and anticancer properties. FAU acts as an antimetabolite, interfering with DNA synthesis by mimicking natural nucleosides and being incorporated into viral or cellular DNA. Its mechanism of action involves selective phosphorylation by herpes simplex virus (HSV) thymidine kinase, leading to preferential incorporation into HSV-infected cells' DNA, thereby inhibiting viral replication while sparing uninfected host cells. Preclinical studies have demonstrated potent anti-herpes simplex virus activity with low toxicity in mammalian models. FAU has also been studied in clinical trials for various lymphomas including mantle cell lymphoma and Waldenström macroglobulinemia[1][2][3][6].
- Other names
- 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
02
Targets
Herpes simplex virus type 2 thymidine kinaseHSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))TK1 (Thymidine kinase 1)
Beyond the preview
Go deeper on 2'-fluoro-5-ethylarabinosyluracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2'-fluoro-5-ethylarabinosyluracil.